Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Construction in Progress (2016 - 2017)

Northwest Biotherapeutics (NWBO) has 3 years of Construction in Progress data on record, last reported at $47.3 million in Q4 2017.

  • For Q4 2017, Construction in Progress rose 6.19% year-over-year to $47.3 million; the TTM value through Dec 2017 reached $47.3 million, up 6.19%, while the annual FY2017 figure was $47.3 million, 6.19% up from the prior year.
  • Construction in Progress reached $47.3 million in Q4 2017 per NWBO's latest filing, roughly flat from $47.3 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $47.3 million in Q3 2017 and bottomed at $44.6 million in Q4 2016.
  • Average Construction in Progress over 3 years is $46.0 million, with a median of $46.0 million recorded in 2015.
  • Peak YoY movement for Construction in Progress: fell 2.46% in 2016, then increased 6.19% in 2017.
  • A 3-year view of Construction in Progress shows it stood at $45.7 million in 2015, then fell by 2.46% to $44.6 million in 2016, then rose by 6.19% to $47.3 million in 2017.
  • Per Business Quant database, its latest 3 readings for Construction in Progress were $47.3 million in Q4 2017, $47.3 million in Q3 2017, and $46.2 million in Q2 2017.